2m 2m 2m 2m 2m 2m 2m
THERIVA BIO (TOVX)
NYSE
$0.28-$0.007 (-2.45%)
Price as of Jun 03, 2026 7:14 PM EDT- $13.0MMarket Cap
- -39.15%1-Year Change
- BiotechnologyIndustry
THERIVA BIO (TOVX)
$0.28-$0.007 (-2.45%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -8.6M -28.48% | -12.0M -15.93% | -14.3M +22.08% | -11.7M +50.29% | |
Depreciation and Amortization Expense | 108,000 -21.17% | 137,000 +1.48% | 135,000 +58.82% | 85,000 -2.30% | |
Total Operating Expenses | 24.1M -8.71% | 26.3M +22.93% | 21.4M -0.70% | 21.6M +51.19% | |
Operating Profit | -24.1M -8.71% | -26.3M +22.93% | -21.4M -0.70% | -21.6M +51.19% | |
Interest Income | 287,000 -58.82% | 697,000 -51.56% | 1.4M +181.05% | 512,000 +8,433.33% | |
Interest Expense | -61,000 N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 226,000 -67.58% | 697,000 -51.56% | 1.4M +181.05% | 512,000 +8,433.33% | |
Total Nonoperating Income and Expense | 312,000 -54.98% | 693,000 -51.94% | 1.4M +206.16% | 471,000 +7,750.00% | |
Income before Taxes | -23.7M -7.46% | -25.7M +28.34% | -20.0M -5.31% | -21.1M -8.97% | |
Income Taxes | N/A N/A | 0 +100.00% | -1.6M +15.09% | -1.4M N/A | |
Extraordinary Items | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Net Income | -23.7M -7.46% | -25.7M +39.81% | -18.3M -6.79% | -19.7M +37.98% | |
Net Income from Continuing Operations Applicable to Common | -25.2M -1.57% | -25.7M +39.81% | -18.3M -8.37% | -20.0M -13.64% | |
Basic EPS and Net Income | -2.08 -89.07% | -19.03 +1,569.30% | -1.14 -12.98% | -1.31 +589.47% | |
Diluted EPS and Net Income | -2.08 -89.07% | -19.03 +1,569.30% | -1.14 -12.98% | -1.31 +589.47% | |
Basic Weighted Average Shares | 12.1M +800.56% | 1.3M -91.63% | 16.1M +5.09% | 15.3M -87.42% | |
Diluted Weighted Average Shares | 12.1M +800.56% | 1.3M -91.63% | 16.1M +5.09% | 15.3M -87.42% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 13.1M +12.46% | 11.6M -49.91% | 23.2M -44.53% | 41.8M -37.93% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 13.1M +12.46% | 11.6M -49.91% | 23.2M -44.53% | 41.8M -37.93% | |
Total Current Assets | 17.5M +7.28% | 16.3M -40.59% | 27.4M -39.80% | 45.5M -33.89% | |
Accumulated Depreciation | 966,000 +3.32% | 935,000 -6.69% | 1.0M +15.84% | 865,000 +4.09% | |
Property and Plant and Equipment and Net | 222,000 -17.78% | 270,000 -36.02% | 422,000 +22.32% | 345,000 +241.58% | |
Total Long-Term Assets | 222,000 -17.78% | 270,000 -36.02% | 422,000 +22.32% | 345,000 +241.58% | |
Total Assets | 38.2M +8.17% | 35.4M -35.98% | 55.2M -23.16% | 71.9M +2.13% | |
Income Taxes Payable | 842,000 -64.92% | 2.4M +48.33% | 1.6M 0.00% | 1.6M +131.14% | |
Total Short-Term Debt | 57,000 -6.56% | 61,000 -3.17% | 63,000 +10.53% | 57,000 N/A | |
Total Current Liabilities | 10.0M +32.02% | 7.6M +12.57% | 6.7M -4.56% | 7.1M +98.65% | |
Total Long-Term Debt | 1.7M +1,716.30% | 92,000 -43.21% | 162,000 -26.70% | 221,000 N/A | |
Total Long-Term Liabilities | 352,000 -59.68% | 873,000 -84.37% | 5.6M +26.25% | 4.4M +215.25% | |
Total Liabilities | 22.9M +40.35% | 16.3M +4.92% | 15.5M -10.26% | 17.3M +248.94% | |
Retained Earnings | -358.7M +7.09% | -335.0M +8.29% | -309.3M +6.31% | -291.0M +7.26% | |
Total Stockholders Equity | 15.4M -19.32% | 19.1M -48.42% | 37.0M -28.68% | 51.8M -20.76% | |
Total Shares Outstanding | 35.7M +1,182.62% | 2.8M -83.77% | 17.1M +13.38% | 15.1M -88.55% | |
Cash Flow | |||||
Cash from Operating Activities | -16.7M -1.58% | -16.9M -10.84% | -19.0M -0.45% | -19.1M +48.04% | |
Capital Expenditures | 35,000 +3,400.00% | 1,000 -99.50% | 202,000 +74.14% | 116,000 +728.57% | |
Cash from Investing Activities | -35,000 +3,400.00% | -1,000 -99.50% | -202,000 -95.40% | -4.4M +31,300.00% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 18.2M +231.02% | 5.5M +779.36% | 625,000 +132.38% | -1.9M -102.61% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Return on Assets | -64.52% +13.89% | -56.65% +96.16% | -28.88% +4.32% | -27.68% -23.58% | |
Return on Equity | -137.82% +50.51% | -91.57% +121.56% | -41.33% +23.07% | -33.58% -28.63% | |
Revenue Growth | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Current Ratio | 1.74 -18.74% | 2.15 -47.22% | 4.07 -36.92% | 6.45 -66.72% | |
Cash Ratio | 1.30 -14.81% | 1.53 -55.50% | 3.44 -41.88% | 5.92 -68.76% | |
Debt-to-Equity Ratio | 0.11 +1,303.75% | 0.008 +31.15% | 0.006 +12.96% | 0.005 N/A | |
Debt-to-Assets Ratio | 0.05 +951.16% | 0.004 +4.88% | 0.004 +5.13% | 0.004 N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow